{"Abbreviation":"DMT","Aliases":["N,n-dimethyltryptamine","2-(3-Indolyl)ethyldimethylamine","3-(2-Dimethylaminoethyl)indole","1H-Indole-3-ethanamine, N,N-dimethyl-","2-(1H-Indol-3-yl)-N,N-dimethylethanamine","N,N-dimethyl-1H-Indole-3-ethanamine","3-[2-(dimethylamino)ethyl]indole","N-dimethyltryptamine","Indole, 3-(2-(dimethylamino)ethyl)-","Indole, 3-[2-(dimethylamino)ethyl]-"],"Boiling Point":"60-80 °C","CAS":"61-50-7","ChEBI":"CHEBI:28969","ChEMBL":"CHEMBL12420","ChemicalClasses":["tryptamine"],"Chirality":"achiral","Classes":["Psychedelic"],"Color/Form":"Crystals ... also reported as plates from ethanol and light petroleum","DEA no":7435,"Decomposition":"When heated to decomposition if emits toxic fumes of /nitrogen oxides/.","Drug Indication":"Some people use this compound as a psychedelic inducing agent.","DrugClasses":["psychedelic","hallucinogens"],"DurationOfAction":"* Inhalation: ≤30 min\n* Intravenous: ≤30 min\u003ca href='#cite_note-4'\u003e\u003csup\u003e[4]\u003c/sup\u003e\u003c/a\u003e\n* Intramuscular injection|Intramuscular: 30 – 60 min\n* Oral administration|Oral with monoamine oxidase inhibitor: 4 – 6 hours","EINECS":"200-508-4","EliminationHalfLife":"* Alone: 5 – 15 min\n* With an monoamine oxidase inhibitor: 1 – 4 hours","Erowid Experience Reports":[{"Id":"100002","Title":"Love and the Velvet Underground"},{"Id":"100116","Title":"Enter the World of the Strange"},{"Id":"100203","Title":"Interesting / Intriguing New Dimension"},{"Id":"100195","Title":"Temporary Enlightenment"},{"Id":"100248","Title":"Carrier Wave World of Forms, Beings of Light"},{"Id":"100353","Title":"Hyper Dimensional Ganesh Transfers Golden Wisdom"},{"Id":"100724","Title":"Worst 20 Minutes of My Life"},{"Id":"100618","Title":"The Cosmic Clown"},{"Id":"100813","Title":"Met a God"},{"Id":"100929","Title":"Meeting the Mother-God"},{"Id":"100955","Title":"Sooort of Like Skydiving"},{"Id":"101041","Title":"Orally Without an MAOI"},{"Id":"101234","Title":"I Cannot Believe It"},{"Id":"101670","Title":"So Blissfully Happy"},{"Id":"101944","Title":"New Tec"},{"Id":"102100","Title":"Goddess Visions Death Rebirth"},{"Id":"101076","Title":"Infinite Impossibilities"},{"Id":"101112","Title":"Time Travelling to Meet Love Death"},{"Id":"101367","Title":"Touched by God"},{"Id":"101998","Title":"Finally Found What I Was Looking For"},{"Id":"100953","Title":"From “Here, Now” To “THERE-WOW!”"},{"Id":"101222","Title":"The Candyland Dollhouse"},{"Id":"101445","Title":"Thick Light"},{"Id":"101758","Title":"Knowing Energy"},{"Id":"101850","Title":"Relation to Dreams"},{"Id":"101882","Title":"Ego Loss Nothingness Machine Elves"}],"European Community (EC) Number":"200-508-4","FullSalts":["Dimethyltryptamine fumarate","Dimethyltryptamine hydrochloride"],"HMDB ID":"HMDB0005973","HeavyAtomCount":14,"Human Drugs":"Pharmaceuticals","IUPACName":"2-(1H-indol-3-yl)-N,N-dimethylethanamine","InChI":"InChI=1S/C12H16N2/c1-14(2)8-7-10-9-13-12-6-4-3-5-11(10)12/h3-6,9,13H,7-8H2,1-2H3","InChIKey":"DMULVCHRPCFFGV-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise. (See all compounds classified as Hallucinogens.)","Melting Point":"46 °C","MolecularFormula":"C\u003csub\u003e12\u003c/sub\u003eH\u003csub\u003e16\u003c/sub\u003eN\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"188.27 g/mol","Physical Description":"Solid","PrevSalts":["fumarate","hydrochloride"],"PubChemId":6089,"Record Description":["N,N-dimethyltryptamine is a tryptamine derivative having two N-methyl substituents on the side-chain. It is a tryptamine alkaloid and a member of tryptamines. It is functionally related to a tryptamine. It is a conjugate base of a N,N-dimethyltryptaminium.","Dimethyltryptamine is a DEA Schedule I controlled substance. Substances in the DEA Schedule I have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse. It is a Hallucinogenic substances substance.","An N-methylated indoleamine derivative, a serotonergic hallucinogen found in several plants, especially Prestonia amazonica (Apocynaceae) and in mammalian brain, blood, and urine. It apparently acts as an agonist at some types of serotonin receptors and an antagonist at others.","N,N-Dimethyltryptamine has been reported in Acacia confusa, Anadenanthera peregrina, and other organisms with data available.","N,N-DIMETHYLTRYPTAMINE is a small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.","An N-methylated indoleamine derivative and serotonergic hallucinogen which occurs naturally and ubiquitously in several plant species including Psychotria veridis. It also occurs in trace amounts in mammalian brain, blood, and urine, and is known to act as an agonist or antagonist of certain SEROTONIN RECEPTORS.","See also: Dimethyltryptamine fumarate (is active moiety of); Psychotria viridis whole (part of).","N,N-dimethyltryptamine is a tryptamine derivative having two N-methyl substituents on the side-chain. It is a tryptamine alkaloid and a member of tryptamines. It is functionally related to a tryptamine. It is a conjugate base of a N,N-dimethyltryptaminium.","Wikipedia|TiHKAL|Tryptamines"],"RefCount":5,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Dimethyltryptamine","Name":"Dimethyltryptamine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q407217","Name":"Dimethyltryptamine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB01488","Name":"Dimethyltryptamine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/6089","Name":"Dimethyltryptamine","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL12420","Name":"Dimethyltryptamine","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28969","Name":"Dimethyltryptamine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=61-50-7","Name":"Dimethyltryptamine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0005973","Name":"Dimethyltryptamine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C08302","Name":"Dimethyltryptamine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/WUB601BHAA","Name":"Dimethyltryptamine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID60110053","Name":"Dimethyltryptamine","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 6089, Dimethyltryptamine. Accessed June 26, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/6089\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/6089\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Dimethyltryptamine. UNII: WUB601BHAA. Global Substance Registration System. Accessed June 26, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/WUB601BHAA\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/WUB601BHAA\u003c/a\u003e","Anvisa. RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. July 24, 2023. Accessed June 26, 2025. \u003ca href=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451\u003ehttps://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451\u003c/a\u003e","Barker SA. Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT. Psychopharmacology (Berl). June 1, 2022; 239(6):1749–1763."],"SMILES":"CN(C)CCC1=CNC2=CC=CC=C21","Salts":["fumarate","hydrochloride"],"SaltsAcidCount":[1,1],"SaltsAmineCount":[1,1],"SaltsUNII":["EP5189LWFM","PRC2H3HFU4"],"Scheduling":[{"gov":"Australia","ref":[],"schedule":"S9 substance"},{"gov":"Canada","ref":[],"schedule":"Schedule III substance"},{"gov":"United Kingdom","ref":[],"schedule":"Class A substance"},{"act":"Controlled Substances Act (CSA)","gov":"United States","ref":[],"schedule":"Schedule I"},{"gov":"Germany","ref":[],"schedule":"Anlage I substance"},{"gov":"Brazil","ref":["3"],"schedule":"F2 substance"},{"act":"Convention on Psychotropic Substances 1971","gov":"United Nations","ref":[],"schedule":"Schedule I drug"}],"Solubility":"Freely soluble in dilute acetic and dilute mineral acids","StoreUNII":["WUB601BHAA"],"StructureBase64":"PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHhtbG5zOnhsaW5rPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5L3hsaW5rIiBoZWlnaHQ9IjQ2LjI2bW0iIHZlcnNpb249IjEuMiIgdmlld0JveD0iMCAwIDk4LjYzOCA0Ni4yNiIgd2lkdGg9Ijk4LjYzOG1tIj4KICAgICAgCiAgICA8ZGVzYz5HZW5lcmF0ZWQgYnkgdGhlIENoZW1pc3RyeSBEZXZlbG9wbWVudCBLaXQgKGh0dHA6Ly9naXRodWIuY29tL2Nkayk8L2Rlc2M+CiAgICAgIAogICAgPGcgZmlsbD0iIzMwNTBGOCIgc3Ryb2tlPSIjMDAwMDAwIiBzdHJva2UtbGluZWNhcD0icm91bmQiIHN0cm9rZS1saW5lam9pbj0icm91bmQiIHN0cm9rZS13aWR0aD0iLjciPgogICAgICAgICAgICAKICAgICAgICA8cmVjdCBmaWxsPSIjRkZGRkZGIiBoZWlnaHQ9IjQ3LjAiIHN0cm9rZT0ibm9uZSIgd2lkdGg9Ijk5LjAiIHg9Ii4wIiB5PSIuMCIvPgogICAgICAgICAgICAKICAgICAgICA8ZyBjbGFzcz0ibW9sIiBpZD0ibW9sMSI+CiAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICA8bGluZSBjbGFzcz0iYm9uZCIgaWQ9Im1vbDFibmQxIiB4MT0iOTcuNiIgeDI9Ijg3LjU2NCIgeTE9IjI1LjA0MyIgeTI9IjE5LjIzMiIvPgogICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgPGxpbmUgY2xhc3M9ImJvbmQiIGlkPSJtb2wxYm5kMiIgeDE9Ijg0LjQxNiIgeDI9Ijg0LjQzIiB5MT0iMTMuNTU3IiB5Mj0iMi4xNjciLz4KICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgIDxsaW5lIGNsYXNzPSJib25kIiBpZD0ibW9sMWJuZDMiIHgxPSI4MS4yNTciIHgyPSI3MS4yMDQiIHkxPSIxOS4yMjMiIHkyPSIyNS4wMTEiLz4KICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgIDxsaW5lIGNsYXNzPSJib25kIiBpZD0ibW9sMWJuZDQiIHgxPSI3MS4yMDQiIHgyPSI1OC4wMTUiIHkxPSIyNS4wMTEiIHkyPSIxNy4zNzUiLz4KICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgIDxsaW5lIGNsYXNzPSJib25kIiBpZD0ibW9sMWJuZDUiIHgxPSI1OC4wMTUiIHgyPSI0NC44MDciIHkxPSIxNy4zNzUiIHkyPSIyNC45NzkiLz4KICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgIDxnIGNsYXNzPSJib25kIiBpZD0ibW9sMWJuZDYiPgogICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgIDxsaW5lIHgxPSI0My4yMjUiIHgyPSI0NC44MDciIHkxPSI0MC4wOTciIHkyPSIyNC45NzkiLz4KICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICA8bGluZSB4MT0iNDAuOTg1IiB4Mj0iNDIuMTk4IiB5MT0iMzguMDgiIHkyPSIyNi40ODEiLz4KICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICA8L2c+CiAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICA8bGluZSBjbGFzcz0iYm9uZCIgaWQ9Im1vbDFibmQ3IiB4MT0iNDMuMjI1IiB4Mj0iMzEuNjY1IiB5MT0iNDAuMDk3IiB5Mj0iNDIuNTQ4Ii8+CiAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICA8bGluZSBjbGFzcz0iYm9uZCIgaWQ9Im1vbDFibmQ4IiB4MT0iMjYuMjI3IiB4Mj0iMjAuNjg1IiB5MT0iMzkuNTkiIHkyPSIzMC4wNTYiLz4KICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgIDxnIGNsYXNzPSJib25kIiBpZD0ibW9sMWJuZDkiPgogICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgIDxsaW5lIHgxPSI1Ljc3MSIgeDI9IjIwLjY4NSIgeTE9IjI2Ljg4MSIgeTI9IjMwLjA1NiIvPgogICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgIDxsaW5lIHgxPSI3LjY1NSIgeDI9IjE5LjgxNiIgeTE9IjI0Ljc4OCIgeTI9IjI3LjM3NyIvPgogICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgIDwvZz4KICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgIDxsaW5lIGNsYXNzPSJib25kIiBpZD0ibW9sMWJuZDEwIiB4MT0iNS43NzEiIHgyPSIxLjA1NCIgeTE9IjI2Ljg4MSIgeTI9IjEyLjM4Ii8+CiAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICA8ZyBjbGFzcz0iYm9uZCIgaWQ9Im1vbDFibmQxMSI+CiAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgPGxpbmUgeDE9IjExLjI1MiIgeDI9IjEuMDU0IiB5MT0iMS4wNTQiIHkyPSIxMi4zOCIvPgogICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgIDxsaW5lIHgxPSIxMi4xMjIiIHgyPSIzLjgwOSIgeTE9IjMuNzMzIiB5Mj0iMTIuOTY1Ii8+CiAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgPC9nPgogICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgPGxpbmUgY2xhc3M9ImJvbmQiIGlkPSJtb2wxYm5kMTIiIHgxPSIxMS4yNTIiIHgyPSIyNi4xNjYiIHkxPSIxLjA1NCIgeTI9IjQuMjI5Ii8+CiAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICA8ZyBjbGFzcz0iYm9uZCIgaWQ9Im1vbDFibmQxMyI+CiAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgPGxpbmUgeDE9IjMwLjg4MyIgeDI9IjI2LjE2NiIgeTE9IjE4LjczIiB5Mj0iNC4yMjkiLz4KICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICA8bGluZSB4MT0iMjguMTI4IiB4Mj0iMjQuMjgyIiB5MT0iMTguMTQ1IiB5Mj0iNi4zMjEiLz4KICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICA8L2c+CiAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICA8bGluZSBjbGFzcz0iYm9uZCIgaWQ9Im1vbDFibmQxNCIgeDE9IjIwLjY4NSIgeDI9IjMwLjg4MyIgeTE9IjMwLjA1NiIgeTI9IjE4LjczIi8+CiAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICA8bGluZSBjbGFzcz0iYm9uZCIgaWQ9Im1vbDFibmQxNSIgeDE9IjQ0LjgwNyIgeDI9IjMwLjg4MyIgeTE9IjI0Ljk3OSIgeTI9IjE4LjczIi8+CiAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICA8cGF0aCBjbGFzcz0iYXRvbSIgZD0iTTg2LjM1MiAxOS44NTdoLS43MjFsLTIuNjE5IC00LjA2NmgtLjAzcS4wMTIgLjIzOCAuMDMgLjU5NXEuMDI0IC4zNTcgLjAyNCAuNzMzdjIuNzM4aC0uNTY2di00Ljg5OWguNzE1bDIuNjA3IDQuMDU0aC4wM3EtLjAwNiAtLjEwOCAtLjAxOCAtLjMyOHEtLjAxMiAtLjIyIC0uMDI0IC0uNDc2cS0uMDA2IC0uMjYyIC0uMDA2IC0uNDgydi0yLjc2OGguNTc4djQuODk5eiIgaWQ9Im1vbDFhdG0yIiBzdHJva2U9Im5vbmUiLz4KICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgIDxnIGNsYXNzPSJhdG9tIiBpZD0ibW9sMWF0bTgiPgogICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgIDxwYXRoIGQ9Ik0zMC4yOTYgNDUuN2gtLjcyMWwtMi42MTkgLTQuMDY2aC0uMDNxLjAxMiAuMjM4IC4wMyAuNTk2cS4wMjQgLjM1NyAuMDI0IC43MzJ2Mi43MzhoLS41NjZ2LTQuODk5aC43MTVsMi42MDcgNC4wNTRoLjAzcS0uMDA2IC0uMTA3IC0uMDE4IC0uMzI4cS0uMDEyIC0uMjIgLS4wMjQgLS40NzZxLS4wMDYgLS4yNjIgLS4wMDYgLS40ODJ2LTIuNzY4aC41Nzh2NC44OTl6IiBzdHJva2U9Im5vbmUiLz4KICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICA8cGF0aCBkPSJNMjUuODUzIDQ1LjdoLS42MTl2LTIuMjg2aC0yLjUxM3YyLjI4NmgtLjYxM3YtNC44OTloLjYxM3YyLjA3MWgyLjUxM3YtMi4wNzFoLjYxOXY0Ljg5OXoiIHN0cm9rZT0ibm9uZSIvPgogICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgIDwvZz4KICAgICAgICAgICAgICAgIAogICAgICAgICAgICA8bGluZSBjbGFzcz0iaGkiIGlkPSJtb2wxYm5kMSIgc3Ryb2tlPSIjMzA1MEY4IiB4MT0iODcuNTY0IiB4Mj0iOTIuNTgyIiB5MT0iMTkuMjMyIiB5Mj0iMjIuMTM3NSIvPgogICAgICAgICAgICA8bGluZSBjbGFzcz0iaGkiIGlkPSJtb2wxYm5kMiIgc3Ryb2tlPSIjMzA1MEY4IiB4MT0iODQuNDE2IiB4Mj0iODQuNDIzIiB5MT0iMTMuNTU3IiB5Mj0iNy44NjIiLz4KICAgICAgICAgICAgPGxpbmUgY2xhc3M9ImhpIiBpZD0ibW9sMWJuZDMiIHN0cm9rZT0iIzMwNTBGOCIgeDE9IjgxLjI1NyIgeDI9Ijc2LjIzMDUiIHkxPSIxOS4yMjMiIHkyPSIyMi4xMTY5OTk5OTk5OTk5OTciLz4KICAgICAgICAgICAgPGxpbmUgY2xhc3M9ImhpIiBpZD0ibW9sMWJuZDciIHN0cm9rZT0iIzMwNTBGOCIgeDE9IjMxLjY2NSIgeDI9IjM3LjQ0NSIgeTE9IjQyLjU0OCIgeTI9IjQxLjMyMjUwMDAwMDAwMDAwNSIvPgogICAgICAgICAgICA8bGluZSBjbGFzcz0iaGkiIGlkPSJtb2wxYm5kNyIgc3Ryb2tlPSIjMzA1MEY4IiB4MT0iMzEuNjY1IiB4Mj0iMzcuNDQ1IiB5MT0iNDIuNTQ4IiB5Mj0iNDEuMzIyNTAwMDAwMDAwMDA1Ii8+CiAgICAgICAgICAgIDxsaW5lIGNsYXNzPSJoaSIgaWQ9Im1vbDFibmQ4IiBzdHJva2U9IiMzMDUwRjgiIHgxPSIyNi4yMjciIHgyPSIyMy40NTYiIHkxPSIzOS41OSIgeTI9IjM0LjgyMyIvPgogICAgICAgICAgICA8bGluZSBjbGFzcz0iaGkiIGlkPSJtb2wxYm5kOCIgc3Ryb2tlPSIjMzA1MEY4IiB4MT0iMjYuMjI3IiB4Mj0iMjMuNDU2IiB5MT0iMzkuNTkiIHkyPSIzNC44MjMiLz4KICAgICAgICA8L2c+CiAgICAgICAgICAKICAgIDwvZz4KICAgIAo8L3N2Zz4K","Subjective Effects":null,"Title":"Dimethyltryptamine","UNII":"WUB601BHAA","Wikidata":"Q407217","Wikipedia":"Dimethyltryptamine","XLogP":2.5}